These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28604155)

  • 1. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.
    Cullen LM; Schmidt MR; Morrison TG
    Hum Vaccin Immunother; 2017 Dec; 13(12):2814-2823. PubMed ID: 28604155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
    McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
    J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.
    Cullen LM; Blanco JC; Morrison TG
    J Transl Med; 2015 Nov; 13():350. PubMed ID: 26541285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.
    Schmidt MR; McGinnes-Cullen LW; Kenward SA; Willems KN; Woodland RT; Morrison TG
    J Virol; 2014 Sep; 88(17):10165-76. PubMed ID: 24965456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.
    McGinnes Cullen L; Luo B; Wen Z; Zhang L; Durr E; Morrison TG
    J Virol; 2023 Jan; 97(1):e0190022. PubMed ID: 36602367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains.
    Schmidt MR; McGinnes LW; Kenward SA; Willems KN; Woodland RT; Morrison TG
    J Virol; 2012 Nov; 86(21):11654-62. PubMed ID: 22896618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
    Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
    Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
    Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
    J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Trinité B; Durr E; Pons-Grífols A; O'Donnell G; Aguilar-Gurrieri C; Rodriguez S; Urrea V; Tarrés F; Mane J; Ortiz R; Rovirosa C; Carrillo J; Clotet B; Zhang L; Blanco J
    Vaccine; 2024 May; 42(15):3474-3485. PubMed ID: 38641492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two RSV Platforms for G, F, or G+F Proteins VLPs.
    Ha B; Yang JE; Chen X; Jadhao SJ; Wright ER; Anderson LJ
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32824936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.